Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:9
  • preuzimanja u poslednjih 30 dana:0
članak: 6 od 21  
Back povratak na rezultate
Acta Facultatis Medicae Naissensis
2010, vol. 27, br. 3, str. 125-134
jezik rada: engleski
vrsta rada: izvorni naučni članak

Dostizanje ciljnih vrednosti krvnog pritiska kod bolesnika sa preležanim infarktom miokarda i šećernom bolešću
aZdravstveni centar, Pirot
bDom zdravlja, Leskovac
cUniverzitet u Nišu, Medicinski fakultet, Institut za prevenciju, lečenje i rehabilitaciju reumatičkih i kardioloških bolesti 'Niška Banja' - Niška Banja

e-adresa: emina.aleksic@yahoo.com

Sažetak

Iako je arterijska hipertenzija važan faktor koji doprinosi kardiovaskularnim komplikacijama kod koronarnih bolesnika sa i bez dijabetesa mellitusa (DM), dostizanje ciljnih vrednosti krvnog pritiska se u praksi retko ostvaruje. Cilj ove studije bio je da se uporedi dostizanje ciljnih vrednosti krvnog pritiska kod bolesnika sa preživelim infarktom miokarda (IM) koji imaju DM (grupa A) sa onima koji nemaju DM (grupa B) . Tokom istraživanja praćena je u trogodišnjem periodu grupa od 118 bolesnika, 34 pripadalo je grupi A i 84 grupi B, oba pola sa potvrđenom dijagnozom IM. Posle trogodišnjeg sprovođenja mera sekundarne prevencije bolesnici grupe B imali su veću zastupljenost ciljnih vrednosti krvnog pritiska (TA<140/90mmHg) u odnosu na početak istraživanja (84.8% prema 28.6%) (p<0.0001). Bolesnici grupe A nemaju statistički značajno veću zastupljenost ciljnih vrednosti krvnog pritiska (TA<130/80mmHg) na kraju istraživanja (11.8% prema 24.2%) (p>0.05), ali je zato njihov procenat sa vrednostima TA<140/90mmHg statistički značajno veći (57.6% prema 18.2%) (p<0.0005). Analiza primene mera sekundarne prevencije pokazala je da 21.3% bolesnika grupe A i 12.7% grupe B nije uzimalo β-blokatore, ali razlika nije statistički signifikantna (p>0.05). Takođe, u pogledu uzimanja ACE inhibitora nema statistički signifikantne razlike između grupe A (84.8%) i grupe B (89.8%) (p>0.05). Naša studija o evaluaciji mera sekundarne prevencije u pogledu dostizanja ciljnih vrednosti krvnog pritiska kod bolesnika sa/bez DM i preležanim IM, pokazala je visoku prevalencu povišenih vrednosti krvnog pritiska, naročito u grupi sa DM, kao i još uvek nedovoljnu upotrebu β-blokatora i ACE inhibitora. Stoga treba intenzivirati mere sekundarne prevencije kardiovaskularnih događaja, naročito kod bolesnika sa dijabetesom.

Ključne reči

ciljne vrednosti krvnog pritiska; dijabetičari i infarkt miokarda; nedijabetičari i infarkt miokarda; sekundarna prevencija

Reference

Aguilar, D., Solomon, S.D., Kober, L., Rouleau, J., Skali, H., i dr. (2004) Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 110(12): 1572-8
Akbar, D.H. (2000) Secondary Prevention Measures after Acute Myocardial Infarction: Comparison between Diabetics and Non-Diabetics at a Saudi Teaching Hospital. Medical Principles and Practice, 9(3): 181-185
Aleksić, E.D., Stamenković, R.Lj., Đorđeviđ, D.B., Lazarević, G.D., Vulić, D.B., Tasić, I.S. (2010) Prognostic factors in patients who have survived myocardial infarction
Anselmino, M., Bartnik, M., Malmberg, K., Ryden, L., Euro Heart Survey Investigators (2007) Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart. Eur J Cardiovasc Prev Rehab, 14:28-36
Assmann, G., Schulte, H. (1988) The Prospective Cardiovascular Münster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J, 116(6 Pt 2): 1713-24
Bartnik, M., Malmberg, K., Hamsten, A., Efendic, S., Norhammar, A., Silveira, A., Tenerz, A., Ohrvik, J., Ryden, L. (2004) Abnormal glucose tolerance: A common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med, 256(4): 288-97
Brand, D.A., Newcomer, L.N., Freiburger, A., Tian, H. (1995) Cardiologists' practices compared with practice guidelines: Use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol, 26(6): 1432-6
Chen, J., Marciniak, T.A., Radford, M.J., Wang, Y., Krumholz, H.M. (1999) Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. Journal of the American College of Cardiology, 34(5): 1388-94
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42(6): 1206-52
Chowdhury, T.A., Lasker, S.S., Dyer, P.H. (1999) Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus. Journal of internal medicine, 245(6): 565-70
d'Agostino R.B., Belanger, A.J., Kannel, W.B., Cruickshank, J.M. (1991) Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: The Framingham Study. BMJ, 303(6799): 385-9
European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21(6): 1011-53
Flack, J.M., Neaton, J., Grimm, R., Shih, J., Cutler, J., Ensrud, K., MacMahon, S. (1995) Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation, 92(9): 2437-45
Franklin, K., Goldberg, R.J., Spencer, F., Klein, W., Budaj, A., Brieger, D., Marre, M., Steg, P.G., Gowda, N., Gore, J.M., GRACE Investigators (2004) Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med, 164(13): 1457-63
Graham, I., Atar, D., Borch-Johansen, K., Boysen, G., Burrel, G., Cifkova, R., i dr. (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and the Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 1-40
Gustafsson, I., Torp-Pedersen, C., Køber, L., Gustafsson, F., Hildebrandt, P. (1999) Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol, 34:839
Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339(4): 229-34
Ho, M.P., Masoudi, F.A., Peterson, E.D., Grunwald, G.K., Sales, A.E., Hammermeister, K.E., Rumsfeld, J.S. (2004) Cardiology management improves secondary prevention measures among patients with coronary artery disease. Journal of the American College of Cardiology, 43(9): 1517-23
Kannel, W.B., McGee, D.L. (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care, 2(2): 120-6
Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., i dr. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension, 25(6): 1105-87
Mcguire, D.K., Emanuelsson, H., Granger, C.B., Magnus, O.E., Moliterno, D.J., White, H.D., Ardissino, D., Box, J.W., Califf, R.M., Topol, E.J. (2000) Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J, 21(21): 1750-8
Norhammar, A., Malmberg, K., Ryden, L., Tornvall, P., Stenestrand, U., Wallentin, L., Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA) (2003) Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J, 24(9): 838-44
Norhammar, A., Tenerz, A., Nilsson, G., Hamsten, A., Efendic, S., Ryden, L., Malmberg, K. (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet, 359(9324):2140-4
O'Brien, E., Asmar, R., Beilin, L., Imai, Y., Mallion, J., Mancia, G., Mengden, T., Myers, M., Padfield, P., Palatini, P., Parati, G., Pickering, T., Redon, J., Staessen, J., Stergiou, G. (2003) European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens, 21(5): 821-48
Pyörälä, K., Lehto, S., de Bacquer, D., de Sutter, J., Sans, S., Keil, U., Wood, D., de Backer, G. (2004) Risk factor management in diabetic and non-diabetic patients with coronary heart disease: Findings from the EUROASPIRE I AND II surveys. Diabetologia, 47(7): 1257-65
Ryden, L., Standl, E., Bartnik, M., van Berghe, G., Betteridge, J., Boer, M., i dr. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. European Heart Journal, 28(1), 88-126
Savić, T., Janković, D., Janković, I., Bojanić, V., Đinđić, B., Miladinović-Tasić, N., Tasić, I. (2010) Efekti terapije simvastatinom na mineralnu gustinu kosti kod žena sa hiperholesterolemijom u postmenopauzalnom periodu. Acta facultatis medicae Naissensis, vol. 27, br. 1, str. 13-18
Saydah, S.H., Fradkin, J., Cowie, C.C. (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA, 291(3): 335-42
Sicras-Mainar, A., Navarro-Artieda, R., Rejas-Gutiérrez, J., Fernández--Bobadilla, J., Frías-Garrido, X., Ruiz-Riera, R. (2007) Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. BMC family practice, 8: 60
Sicree, R., Shaw, J.E., Zimmet, P.Z. (2006) The Global Burden of Diabetes. u: Gan D. [ur.] Diabetes Atlas, Brussels: International Diabetes Federation
Tenerz, A., Lonnberg, I., Berne, C., Nilsson, G., Leppert, J. (2001) Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes?. Eur Heart J, 22(13): 1102-10
Timmer, J.R., Horst, I.C.C., Luca, G., Ottervanger, J.P., Hoorntje, J.C.A., Boer, M., Suryapranata, H., Dambrink, J.E., Gosselink, M., Zijlstra, F., Hof, A.W.J. (2005) Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. American journal of cardiology, 95(11): 1375-7
UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317(7160): 703-13
Völler, H., Reibis, R., Pittrow, D., Jannowitz, C., Wegscheider, K., Karmann, B., Bestehorn, K. (2009) Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: risk factors, treatment and target level attainment. Current medical research and opinion, 25(4): 879-90
Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342(3): 145-53
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., Lisheng, L., INTERHEART.Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 364(9438): 937-52
Zuanetti, G., Latini, R., Maggioni, A.P., Franzosi, M., Santoro, L., Tognoni, G. (1997) Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation, 96(12): 4239-45